Norwe - Kinorwe - Statens legemiddelverk

bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 100 mg

Norwe - Kinorwe - Statens legemiddelverk

fresenius kabi norge as - halden - kromkloridheksahydrat / kobberkloriddihydrat / jern(iii)kloridheksahydrat / mangankloridtetrahydrat / kaliumjodid / natriumfluorid / natriummolybdatdihydrat / sinkklorid / natriumselenitt - konsentrat til infusjonsvæske - 5.33 mikrog/ ml / 0.34 mg/ ml / 0.54 mg/ ml / 99 mikrog/ ml / 16.6 mikrog/ ml / 0.21 mg/ ml / 4.85 mikrog/ ml / 1.36 mg/ ml / 6.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

serb sa - betaine - homocystinuria - andre alimentary tract and metabolism products, - amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:•         cystathionine beta-synthase (cbs),•         5,10 methylene tetrahydrofolate reductase (mthfr),•         cobalamin cofactor metabolism (cbl).